Man Group’s Vaxcyte PCVX Stock Holding History

Man Group’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.75M	Buy	81,632 +62,375	+324%	+$3.39M	0.01%	1164
2026 Q1	$1.12M	Sell	19,257 -49,656	-72%	-$2.7M	﹤0.01%	1795
2025 Q4	$3.18M	Sell	68,913 -175,984	-72%	-$7.87M	0.01%	1266
2025 Q3	$8.82M	Buy	244,897 +215,402	+730%	+$7.14M	0.02%	853
2025 Q2	$959K	Sell	29,495 -739	-2%	-$24.2K	﹤0.01%	1642
2025 Q1	$1.14M	Sell	30,234 -112,192	-79%	-$8.97M	﹤0.01%	1554
2024 Q4	$11.7M	Buy	142,426 +127,875	+879%	+$12.7M	0.03%	669
2024 Q3	$1.66M	Buy	+14,551	New	+$1.31M	﹤0.01%	1369
2023 Q1	–	Hold	0	–	–	–	1349

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Man Group's PCVX Position: Q2 2026 in Review

Man Group increased its Vaxcyte (PCVX) stake by 324% in Q2 2026, buying an estimated $3.39M and bringing the position to 81,632 shares worth $4.75M. The position accounts for 0.01% of the portfolio, ranked #1164.

Man Group first reported a position in PCVX in Q3 2024 and has held it in 8 quarters since. The position peaked at $11.7M in Q4 2024. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

Man Group held 81,632 shares of Vaxcyte worth $4.75M as of Q2 2026.
Man Group bought 62,375 Vaxcyte shares in Q2 2026, an estimated $3.39M.
Vaxcyte made up 0.01% of Man Group's portfolio in Q2 2026, its #1164 holding.
Man Group first reported a position in Vaxcyte in Q3 2024 and has held it in 8 quarters since.
Man Group's Vaxcyte position peaked at $11.7M in Q4 2024.
331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.